/DNLI
Denali Therapeutics Inc.
DNLI • NASDAQDNLI • NASDAQ • Healthcare
$20.65+4.93%+0.97
$20.65+4.93%(+0.97)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
77Low Risk
Momentum
80Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
—
Revenue after COGS
Operating
—
After operating expenses
Net
—
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-5.7
Price vs earnings
EV/EBITDA
-5.5
Enterprise value
FCF Yield
-14.6%
Cash generation
Earnings Yield
-17.7%
Inverse of P/E
Capital Efficiency
-50
GoAI Quality ScorePoor
ROEReturn on Equity
-50.6%Weak
ROAReturn on Assets
-44.8%Weak
ROICReturn on Invested Capital
-52.6%Weak
Financial Health
Current RatioHealthy
9.16
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.33x
Debt repayment capacity (<3x)
Income QualityFair
0.81
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $330.53M | $108.46M | $48.66M |
| Gross Profit | -$11.18M | N/A | $330.53M | $108.46M | $48.66M |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | -$555.34M | -$487.34M | -$196.70M | -$340.74M | -$295.75M |
| Net Income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -$290.58M |
| Net Margin | N/A | N/A | -43.9% | -300.6% | -597.2% |
| EPS | -$2.97 | -$2.57 | -$1.06 | -$2.60 | -$2.39 |
Average Price Target
$34.40▲ 66.6% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Denali Therapeutics Inc., the average price target is $34.40, with a high forecast of $40.00 and a low forecast of $25.00. The average price target represents a 66.6% increase from the current price of $20.65.
Highest
$40.00
Average
$34.40
Lowest
$25.00
Rating Distribution
Strong Buy
0
0%
Buy
17
100%
Hold
0
0%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Baird● Maintain
Outperform
2026-03-26HC Wainwright & Co.● Maintain
Buy
2026-03-26Morgan Stanley● Maintain
Overweight
2026-03-26Goldman Sachs● Maintain
Buy
2026-03-26Stifel● Maintain
Buy
2026-03-26BTIG● Maintain
Buy
2026-03-25BTIG● Maintain
Buy
2026-03-02BTIG● Maintain
Buy
2026-02-06Wedbush● Maintain
Outperform
2025-12-11BTIG● Maintain
Buy
2025-12-05Earnings History & Surprises
BEAT RATE
50%
Last 18 quarters
AVG SURPRISE
+11.9%
EPS vs Estimate
BEATS / MISSES
9/9
Last 18 quarters
LATEST EPS
$-0.73
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+2.7%
$-0.73 vs $-0.75
Q4 '25
+2.6%
$-0.74 vs $-0.76
Q3 '25
+2.7%
$-0.72 vs $-0.74
Q2 '25
-9.9%
$-0.78 vs $-0.71
Q1 '25
+10.7%
$-0.67 vs $-0.75
Q4 '24
-5.0%
$-0.63 vs $-0.60
Q3 '24
+13.2%
$-0.59 vs $-0.68
Q2 '24
-1.5%
$-0.68 vs $-0.67
Q1 '24
-4.9%
$-0.86 vs $-0.82
Q4 '23
+13.3%
$-0.72 vs $-0.83
Q3 '23
+291.2%
$1.30 vs $-0.68
Q2 '23
-12.7%
$-0.80 vs $-0.71
No investor questions available.
Latest News
No news available